RU2015133801A - Lyophilized formulations for parenteral use - Google Patents

Lyophilized formulations for parenteral use Download PDF

Info

Publication number
RU2015133801A
RU2015133801A RU2015133801A RU2015133801A RU2015133801A RU 2015133801 A RU2015133801 A RU 2015133801A RU 2015133801 A RU2015133801 A RU 2015133801A RU 2015133801 A RU2015133801 A RU 2015133801A RU 2015133801 A RU2015133801 A RU 2015133801A
Authority
RU
Russia
Prior art keywords
lyophilized formulations
vials
solution
nitrogen
formulations according
Prior art date
Application number
RU2015133801A
Other languages
Russian (ru)
Inventor
Раджеш Кумар МИШРА
Original Assignee
Камус Фарма Пвт. Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Камус Фарма Пвт. Лтд. filed Critical Камус Фарма Пвт. Лтд.
Publication of RU2015133801A publication Critical patent/RU2015133801A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Claims (22)

1. Лиофилизированные составы, содержащие по меньшей мере одно производное рифамицина и по меньшей мере одно вспомогательное вещество.1. Lyophilized formulations containing at least one rifamycin derivative and at least one excipient. 2. Лиофилизированные составы по п. 1, отличающиеся тем, что производное рифамицина представляет собой рифабутин.2. Lyophilized formulations according to claim 1, characterized in that the rifamycin derivative is rifabutin. 3. Лиофилизированные составы по п. 1, отличающиеся тем, что данные составы содержат от 40 до 80 миллиграмм рифабутина.3. Lyophilized formulations according to claim 1, characterized in that these formulations contain from 40 to 80 milligrams of rifabutin. 4. Лиофилизированные составы по п. 1, отличающиеся тем, что состав вводят в парентеральной форме.4. Lyophilized formulations according to claim 1, characterized in that the composition is administered in parenteral form. 5. Лиофилизированные составы по п. 4, отличающиеся тем, что состав вводят в форме инъекции.5. Lyophilized formulations according to claim 4, characterized in that the composition is administered in the form of an injection. 6. Способ получения лиофилизированных составов по п. 1, включающий сублимационную сушку раствора, содержащего производное рифамицина, солюбилизатор и стабилизатор.6. A method for producing lyophilized formulations according to claim 1, including freeze-drying a solution containing a rifamycin derivative, a solubilizer and a stabilizer. 7. Способ по п. 6, отличающийся тем, что стадия способа сублимационной сушки включает последовательные этапы охлаждения и нагревания.7. The method according to p. 6, characterized in that the stage of the method of freeze-drying includes successive stages of cooling and heating. 8. Способ по п. 6, отличающийся тем, что способ осуществляют в условиях вакуума.8. The method according to p. 6, characterized in that the method is carried out under vacuum. 9. Способ по п. 6, отличающийся тем, что способ дополнительно включает дополнительные циклы сушки.9. The method according to p. 6, characterized in that the method further includes additional drying cycles. 10. Способ получения флаконов с лиофилизированным составом включающий следующие стадии:10. A method of obtaining vials with a lyophilized composition comprising the following stages: a) перенос воды для инъекций в сосуд;a) transferring water for injection into a vessel; b) продувка сосуда азотом в течение 15 мин;b) purging the vessel with nitrogen for 15 minutes; c) смешивание Рифабутина, вспомогательных веществ и разбавителей в сосуде с непрерывной продувкой азотом до тех пор, пока раствор не станет прозрачным;c) mixing Rifabutin, excipients and diluents in a vessel with continuous nitrogen purging until the solution becomes clear; d) перенос раствора для фильтрации;d) transferring the filtration solution; e) необязательно барботирование стерильным азотом основного объема раствора;e) optionally sparging with sterile nitrogen the bulk of the solution; f) заполнение фильтрованным раствором стерильных флаконов;f) filling with a filtered solution of sterile vials; g) загрузка полузакрытых флаконов на полку лиофилизатора;g) loading half-closed vials onto a lyophilizer shelf; h) закрытие двери лиофилизатора после завершения операции заполнения;h) closing the lyophilizer door after completion of the filling operation; i) запуск цикла лиофилизации, после которого флаконы помещают с помощью гидравлической системы в вакуум;i) starting the lyophilization cycle, after which the bottles are placed in a vacuum using a hydraulic system; j) нарушение вакуума путем подачи фильтрованного азота;j) violation of the vacuum by supplying filtered nitrogen; k) выгрузка флаконов из лиофилизатора; иk) unloading the vials from the lyophilizer; and l) запаивание флаконов.l) sealing of vials.
RU2015133801A 2014-01-09 2015-01-08 Lyophilized formulations for parenteral use RU2015133801A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN67/DEL/2014 2014-01-09
IN67DE2014 2014-01-09
PCT/IB2015/050140 WO2015104668A2 (en) 2014-01-09 2015-01-08 Lyophilized formulations for parenteral use

Publications (1)

Publication Number Publication Date
RU2015133801A true RU2015133801A (en) 2017-02-16

Family

ID=53524442

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015133801A RU2015133801A (en) 2014-01-09 2015-01-08 Lyophilized formulations for parenteral use

Country Status (2)

Country Link
RU (1) RU2015133801A (en)
WO (1) WO2015104668A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2993661A1 (en) * 2015-08-04 2017-02-09 Rigel Pharmaceuticals, Inc. Benzazole compounds and methods for making and using the compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA021117B1 (en) * 2010-12-27 2015-04-30 Ооо "Научно-Производственный Комплекс "Наносистема" Method for producing a water-soluble pharmaceutical composition of an antibiotic from the group consisting of rifamycins, and pharmaceutical composition for treating tuberculosis and diseases associated with helicobacter pylori
RU2481109C1 (en) * 2012-03-20 2013-05-10 Закрытое акционерное общество "Брынцалов-А" Parenteral drug preparation of rifabutin for therapy of human and animal infectious diseases

Also Published As

Publication number Publication date
WO2015104668A3 (en) 2015-11-12
WO2015104668A2 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
RU2018110333A (en) STABLE PHARMACEUTICAL PRODUCT BASED ON AN ANTIBODY TO PD-1 AND ITS APPLICATION IN MEDICINE
JP2006520787A5 (en)
DE18190279T1 (en) Pharmaceutical Anti-TNF-ALPHA Antibody Formulation
JP2011524224A (en) Method for filling a dual chamber system in a pre-sterilizable support system and a pre-sterilizable support system
EA201691790A1 (en) METHOD OF PRODUCTING GLASS CLEANER ACETATE PRODUCT
JP2015535243A5 (en)
CN100506213C (en) Lansoprazole freeze-dried powder for injection and preparing method thereof
MX2020001233A (en) Drug compound and purification methods thereof.
EA201991023A1 (en) PHARMACEUTICAL COMPOSITION FOR Parenteral Administration Containing Karglum Acid
RU2015133801A (en) Lyophilized formulations for parenteral use
CN104666303B (en) Freeze-drying process for ganciclovir for injection
PH12019502764A1 (en) Compounds and compositions for inducing chondrogenesis
CU20200017A7 (en) STABLE SOLID, LYOPHILIZED, CONTAINING WITH PALISIB SUITABLE FOR DILUTION AND THERAPEUTIC APPLICATIONS, AS WELL AS A METHOD FOR ITS RECONSTITUTION
RU2014124143A (en) STABLE COMPOSITION OF ANTIBODY SPECIFICALLY BINDING WITH HER2 RECEPTORS AND METHOD FOR PRODUCING IT
JP6748639B2 (en) Method for supplying dry solid product containing active pharmaceutical ingredient to primary packaging container
CN104188924A (en) Pantoprazole sodium medicine composition for injection
CN103230373A (en) Dexlansoprazole freeze-drying powder for injection and preparation method thereof
CN104173299A (en) Freeze-drying method for injection ligustrazine
TR201905091T4 (en) Method and apparatus for joining a fabric line to a knitted product.
CN105783428B (en) Transition apparatus for freeze dryer
CN113143868B (en) Papaverine hydrochloride for injection and preparation method thereof
CN218650205U (en) High-temperature high-pressure sterilizing pot
서지영 et al. Hyaluronic acid hydrogel as drug carrier for rheumatoid arthritis.
MX2013011767A (en) Solid pharmaceutical composition.
CN104856965B (en) A kind of freeze drying process of injection thymic peptide

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20180109